Where to Bet: How PE Firms Should Allocate AI Investment Across the Portfolio
Most private equity firms managing a portfolio of companies are facing the same pressure right now. The question isn’t whether AI creates value. It’s where, in which company, in what sequence, and fast enough to matter before exit. That is a capital allocation question. It should be governed with exactly the same discipline applied to any other investment decision.
The Portfolio Is Not One Problem
Companies at different stages of operational maturity, with different hold period timelines, different data infrastructures, and different management capacity to absorb change are not the same bet. A mid-hold software platform and a services business eighteen months from exit require fundamentally different AI investment logic. Treating them as if they don’t is where undifferentiated AI spend goes to die.
The first act of discipline is classification: which companies can execute an AI initiative and get it into production fast enough for value to show up before exit, which need foundational work first, and which are simply not the right allocation target right now. The four questions below are how you do that classification with rigor.
Triage before you allocate. Not every company in the portfolio is the right bet at the same time.
Opportunity Identification Is Not a Decision
AI opportunity identification has become its own cottage industry — workshops, maturity assessments, use-case inventories that produce long lists with no mechanism for deciding which ones deserve capital. The output feels productive. The investment decisions it leads to rarely are.
A portfolio company with forty AI use cases identified and none in production is in a worse position than one with two initiatives that are clearly scoped, properly resourced, and on a defined path to deployment. Some firms over-index on thoroughness. Others over-index on speed. Both miss the same thing: decision discipline.
Narrow the list to what can actually be executed and proven within the hold period. Everything else is noise.
A Credible Use Case and an Executable One Are Not the Same Thing
The gap between what looks compelling in a strategy session and what can actually be deployed on real data, in a real workflow, with real users, is where most AI programs stall. Data fragmentation, integration complexity, workflow change, and organizational capacity to absorb it are consistently underestimated across every type of portfolio company.
The triage question is not just “is there value here?” It is “can this organization close the distance between idea and production inside the available window?” That is a harder question, and answering it honestly is what separates firms that build real AI-driven operating leverage from those that accumulate interesting experiments.
Before committing capital, validate execution feasibility as rigorously as you validate the value thesis.
Four Questions Before Any Capital Is Committed
Every AI initiative should answer the same four questions before it gets funded. What value lever does it move — cost, productivity, revenue, pricing, retention? What does execution actually require — data readiness, integration, engineering capacity, change management? What is the realistic time to value, not the optimistic one? And what is the cost of being wrong — how much hold period does a stalled initiative consume?
These are not new questions. They are the same ones applied to any other value creation investment. The discipline breaks down because AI initiatives are often evaluated on a more forgiving standard, on the assumption that the technology itself carries the justification. It doesn’t.
Govern AI investment decisions the same way you govern every other capital allocation. The technology is not the thesis — the economic outcome is.
Pilots Are Not Progress. Production Is.
The discipline breaks down fastest at the pilot stage. Pilots run on simplified data, limited integration, and controlled conditions. They demonstrate possibility, not value.
The capital and time consumed by pilots that were never designed with a production path creates the worst outcome: a hold period that ends with a portfolio of interesting experiments and no demonstrable AI-driven operating leverage to show a buyer.
Design every initiative with production as the starting assumption. If there is no clear production path, there is no initiative worth funding.
Concentrate. Prove. Replicate.
The allocation logic should be simple, even when the execution isn’t. Concentrate investment where value potential and execution feasibility genuinely overlap — not where theoretical upside is highest, and not spread evenly across the portfolio to signal commitment. The companies with the clearest path to production, the data infrastructure to support it, and the management bandwidth to drive it are where early capital goes. Build proof there.
Concentrate capital where feasibility and value align. Prove it in production. That is the sequence that holds.
Replication Is a Discipline, Not a Default
Proving value in one place is necessary. Capturing that value at scale — within a company and across the portfolio — is where the real return on AI investment lives. Most firms stop too early. The initiative works, the numbers move, and the lesson stays trapped inside one team in one company. That is a capital efficiency problem.
Replication within a company is not automatic. A workflow that was redesigned around AI in one business unit does not migrate itself to the next one. The data conditions are different, the integration points are different, and the change management challenge starts over. The sequence that works is deliberate: document what was actually built and why it worked, identify which conditions made it executable, and then assess where those conditions exist elsewhere in the same organization. That is a structured expansion, not a copy-paste.
Replication across the portfolio requires the same rigor applied one level up. When an initiative in a software platform company produces measurable operating leverage — in customer support automation, in pricing intelligence, in sales workflow — the question for the operating partner is not whether it might work somewhere else. The question is which other portfolio company has the data infrastructure, workflow similarity, and management capacity to replicate it within a defined window. Portfolio-wide replication that is not filtered through those three criteria produces the same outcome as undifferentiated AI spend: diffuse effort, no proof, no buyer story.
The firms that build durable AI value across a portfolio treat proven initiatives as institutional assets. They maintain a living inventory of what is in production, what it moves, and what conditions enabled it. They deploy that knowledge deliberately when the conditions match. They do not start from scratch in every company.
Production in one place is proof. Replication across the portfolio is how that proof becomes a return.
Dejan Pokrajac leads HTEC’s Private Equity Partnerships, working with PE firms to identify and execute AI investment opportunities across their portfolios. Connect with Dejan to discuss your portfolio.
